drugset / Trial / NCT04583618
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Primary Objectives: * Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination * Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
Timeline
- Start
- 2020-10-08
- Primary completion
- 2021-08-09
- Completion
- 2022-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | — | Intramuscular |
| Comparator | Prevnar 13 | Vaccine | — | Intramuscular |
| Subject | SP0202-IIb | Vaccine | — | Intramuscular |
| Subject | SP0202-VI | Vaccine | — | Intramuscular |
| Subject | SP0202-VII | Vaccine | — | Intramuscular |
Indications
No indication recorded.